Selective Cytopheretic Inhibitory Device With Regional Citrate Anticoagulation and Portable Sorbent Dialysis
dc.contributor.author | Pino, Christopher J. | en_US |
dc.contributor.author | Farokhrani, Amin | en_US |
dc.contributor.author | Lou, Liandi | en_US |
dc.contributor.author | Smith, Peter L. | en_US |
dc.contributor.author | Johnston, Kimberly | en_US |
dc.contributor.author | Buffington, Deborah A. | en_US |
dc.contributor.author | Humes, H. David | en_US |
dc.date.accessioned | 2013-02-12T19:01:13Z | |
dc.date.available | 2014-04-02T15:08:08Z | en_US |
dc.date.issued | 2013-02 | en_US |
dc.identifier.citation | Pino, Christopher J.; Farokhrani, Amin; Lou, Liandi; Smith, Peter L.; Johnston, Kimberly; Buffington, Deborah A.; Humes, H. David (2013). "Selective Cytopheretic Inhibitory Device With Regional Citrate Anticoagulation and Portable Sorbent Dialysis." Artificial Organs (2): 203-210. <http://hdl.handle.net/2027.42/96390> | en_US |
dc.identifier.issn | 0160-564X | en_US |
dc.identifier.issn | 1525-1594 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/96390 | |
dc.description.abstract | Selective cytopheretic inhibitory device (SCD) therapy is an immunomodulatory treatment provided by a synthetic biomimetic membrane in an extracorporeal circuit, which has shown promise in preclinical large animal models of severe sepsis as well as in clinical trials treating patients with acute kidney injury and multiple organ failure. During SCD therapy, citrate is administered to lower ionized calcium levels in blood for anticoagulation and inhibition of leukocyte activation. Historically, citrate has been known to interfere with sorbent dialysis, therefore, posing a potential issue for the use of SCD therapy with a portable dialysis system. This sorbent dialysis SCD (sorbent SCD) would be well suited for battlefield and natural disaster applications where the water supply for standard dialysis is limited, and the types of injuries in those settings would benefit from SCD therapy. In order to explore the compatibility of sorbent and SCD technologies, a uremic porcine model was tested with the Allient sorbent dialysis system (Renal Solutions Incorporated, Fresenius Medical Care, Warrendale, PA, USA) and concurrent SCD therapy with regional citrate anticoagulation. The hypothesis to be assessed was whether the citrate load required by the SCD could be metabolized prior to recirculation from systemic blood back into the therapeutic circuit. Despite the fact that the sorbent SCD maintained urea clearance without any adverse hematologic events, citrate load for SCD therapy caused an interaction with the sorbent column resulting in elevated, potentially toxic aluminum levels in dialysate and in systemic blood. Alternative strategies to implement sorbent‐SCD therapy will be required, including development of alternate urease‐sorbent column binding chemistry or further changes to the sorbent‐SCD therapeutic circuit along with determining the minimum citrate concentration required for efficacious SCD treatment. | en_US |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Citrate | en_US |
dc.subject.other | Cytopheresis | en_US |
dc.subject.other | Immunomodulation | en_US |
dc.subject.other | Sorbent Dialysis | en_US |
dc.title | Selective Cytopheretic Inhibitory Device With Regional Citrate Anticoagulation and Portable Sorbent Dialysis | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Innovative BioTherapies, Inc. | en_US |
dc.identifier.pmid | 23067378 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/96390/1/aor1541.pdf | |
dc.identifier.doi | 10.1111/j.1525-1594.2012.01541.x | en_US |
dc.identifier.source | Artificial Organs | en_US |
dc.identifier.citedreference | McGill RL, Bakos JR, Ko T, Sandroni SE, Marcus RJ. Sorbent hemodialysis: clinical experience with new sorbent cartridges and hemodialyzers. ASAIO J 2008; 54: 618 – 21. | en_US |
dc.identifier.citedreference | Angus DC, Linde‐Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303 – 10. | en_US |
dc.identifier.citedreference | Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244 – 50. | en_US |
dc.identifier.citedreference | Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344 – 53. | en_US |
dc.identifier.citedreference | Beale R, Reinhart K, Brunkhorst FM, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009; 37: 222 – 32. | en_US |
dc.identifier.citedreference | Ding F, Song J, Jung J, et al. A biomimetic membrance device that modulates the excessive inflammatory response to sepsis. PLoS One 2011; 6: e18584. | en_US |
dc.identifier.citedreference | Ding F, Yevzlin AS, Xu ZY, et al. The effects of a novel therapeutic device on acute kidney injury outcomes in the intensive care unit: a pilot study. ASAIO J 2011; 57: 426 – 32. | en_US |
dc.identifier.citedreference | Humes HD, Sobota JT, Ding F, Song JH. A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure. Blood Purif 2010; 29: 183 – 90. | en_US |
dc.identifier.citedreference | Humes HD, ed. An immunomodulating device to treat multiorgan failure in the ICU. ASAIO Annual Meeting 2011; 2011; Washington DC. | en_US |
dc.identifier.citedreference | Tintinger G, Steel HC, Anderson R. Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clin Exp Immunol 2005; 141: 191 – 200. PMCID: 1809444. | en_US |
dc.identifier.citedreference | Kopp JB, Ball LK, Cohen A, et al. Kidney patient care in disasters: lessons from the hurricanes and earthquake of 2005. Clin J Am Soc Nephrol 2007; 2: 814 – 24. | en_US |
dc.identifier.citedreference | Petersen K, Riddle MS, Danko JR, et al. Trauma‐related infections in battlefield casualties from Iraq. Ann Surg 2007; 245: 803 – 11. PMCID: 1877069. | en_US |
dc.identifier.citedreference | Agar JW. Review: understanding sorbent dialysis systems. Nephrology (Carlton) 2010; 15: 406 – 11. | en_US |
dc.identifier.citedreference | Ash SR. The Allient dialysis system. Semin Dial 2004; 17: 164 – 6. | en_US |
dc.identifier.citedreference | Suki WN, Bonuelous RD, Yocom S, et al. Citrate for regional anticoagulation. Effects on blood PO2, ammonia, and aluminum. ASAIO Trans 1988; 34: 524 – 7. | en_US |
dc.identifier.citedreference | Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294: 184 – 8. | en_US |
dc.identifier.citedreference | Kaiser L, Schwartz KA. Aluminum‐induced anemia. Am J Kidney Dis 1985; 6: 348 – 52. | en_US |
dc.identifier.citedreference | Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN. Osteomalacic dialysis osteodystrophy: evidence for a water‐borne aetiological agent, probably aluminium. Lancet 1978; 1: 841 – 5. | en_US |
dc.identifier.citedreference | Association for the Advancement of Medical Instrumentation. Association for the Advancement of Medical (AAMI) Instrumentation Standards: Dialysis Edition. Arlington, VA: Association for the Advancement of Medical Instrumentation, 2007. | en_US |
dc.identifier.citedreference | Kovalchik MT, Kaehny WD, Hegg AP, Jackson JT, Alfrey AC. Aluminum kinetics during hemodialysis. J Lab Clin Med 1978; 92: 712 – 20. | en_US |
dc.identifier.citedreference | Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450 – 5. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.